SG11202007226UA - Methods and compositions for treating sleep apnea - Google Patents

Methods and compositions for treating sleep apnea

Info

Publication number
SG11202007226UA
SG11202007226UA SG11202007226UA SG11202007226UA SG11202007226UA SG 11202007226U A SG11202007226U A SG 11202007226UA SG 11202007226U A SG11202007226U A SG 11202007226UA SG 11202007226U A SG11202007226U A SG 11202007226UA SG 11202007226U A SG11202007226U A SG 11202007226UA
Authority
SG
Singapore
Prior art keywords
compositions
methods
sleep apnea
treating sleep
treating
Prior art date
Application number
SG11202007226UA
Other languages
English (en)
Inventor
Lawrence G Miller
Barry Wohl
Walter J Lunsmann
Original Assignee
Apnimed Inc Delaware
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Apnimed Inc Delaware filed Critical Apnimed Inc Delaware
Publication of SG11202007226UA publication Critical patent/SG11202007226UA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pulmonology (AREA)
  • Emergency Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
SG11202007226UA 2018-01-30 2019-01-30 Methods and compositions for treating sleep apnea SG11202007226UA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862623892P 2018-01-30 2018-01-30
PCT/US2019/015781 WO2019152475A1 (en) 2018-01-30 2019-01-30 Methods and compositions for treating sleep apnea

Publications (1)

Publication Number Publication Date
SG11202007226UA true SG11202007226UA (en) 2020-08-28

Family

ID=65441079

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202007226UA SG11202007226UA (en) 2018-01-30 2019-01-30 Methods and compositions for treating sleep apnea

Country Status (14)

Country Link
US (3) US11911351B2 (es)
EP (1) EP3746126A1 (es)
JP (2) JP7422666B2 (es)
KR (1) KR20200115598A (es)
CN (1) CN111670050A (es)
AU (1) AU2019214891A1 (es)
BR (1) BR112020015316A2 (es)
CA (1) CA3089712A1 (es)
EA (1) EA202091597A1 (es)
IL (1) IL276247A (es)
MA (1) MA52861A (es)
MX (1) MX2020008086A (es)
SG (1) SG11202007226UA (es)
WO (1) WO2019152475A1 (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2019012729A (es) 2017-04-28 2019-12-19 Brigham & Womens Hospital Inc Metodos y composiciones para el tratamiento de apnea del sue?o.
US20220362221A1 (en) * 2019-11-04 2022-11-17 Apnimed, Inc. (Delaware) Combination pharmacological interventions for multiple mechanisms of obstructive sleep apnea
AU2022231133A1 (en) * 2021-03-04 2023-09-21 Apnimed, Inc. (Delaware) Combination of reboxetine and a muscarinic receptor antagonist (mra) for use in treating sleep apnea
KR20230159462A (ko) * 2021-03-24 2023-11-21 애프니메드, 인코포레이티드 (델라웨어) 수면 무호흡증 치료 방법 및 조성물
KR20240004600A (ko) 2021-05-04 2024-01-11 애프니메드, 인코포레이티드 (델라웨어) (r)-옥시부티닌 d-말레이트의 고체 형태
IL309251A (en) * 2021-06-17 2024-02-01 Apnimed Inc Delaware Norepinephrine reuptake inhibitors for the treatment of sleep apnea
TW202342033A (zh) 2021-12-22 2023-11-01 德商拜耳廠股份有限公司 用於治療睡眠呼吸中止之α２－腎上腺素受體亞型Ｃ（α－２Ｃ）拮抗劑與正腎上腺素再吸收抑制劑之組合
TW202342011A (zh) 2021-12-22 2023-11-01 德商拜耳廠股份有限公司 用於治療睡眠呼吸中止之α２－腎上腺素受體亞型Ｃ（α－２Ｃ）拮抗劑與蕈毒鹼受體拮抗劑之組合
WO2023219991A1 (en) * 2022-05-13 2023-11-16 Apnimed, Inc. (Delaware) Methods and compositions for treating sleep apnea

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL267508A (es) 1960-07-26
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
EP0866711B1 (en) 1995-10-24 2006-07-26 Grünenthal GmbH Montirelin for inhibiting sleep apnea
MXPA02008183A (es) 2000-02-24 2002-11-29 Upjohn Co Combinaciones de farmacos novedosos.
US20020155113A1 (en) 2001-03-13 2002-10-24 Miyoung Chun Methods for treating or preventing cardiovascular disorders by modulating metalloprotease function
US20030060513A1 (en) 2001-09-27 2003-03-27 Arneric Stephen P. Pharmaceutical composition
US20030185882A1 (en) 2001-11-06 2003-10-02 Vergez Juan A. Pharmaceutical compositions containing oxybutynin
US20040235925A1 (en) 2002-12-17 2004-11-25 Pharmacia Corporation Method for the treatment, prevention, or inhibition of a CNS disorder and/or pain and inflammation using a combination of duloxetine, venlafaxine or atomoxetine and a cyclooxygenase-2 selective inhibitor and compositions thereof
US20050009862A1 (en) 2003-04-25 2005-01-13 Sabounjian Luann Method for promoting uninterrupted sleep by administration of trospium chloride
US7550454B2 (en) 2003-12-22 2009-06-23 Acadia Pharmaceuticals, Inc. Amino substituted diaryl[a,d]cycloheptene analogs as muscarinic agonists and methods of treatment of neuropsychiatric disorders
US20060039866A1 (en) 2004-08-20 2006-02-23 Cypress Bioscience, Inc. Method for treating sleep-related breathing disorders
US8252321B2 (en) 2004-09-13 2012-08-28 Chrono Therapeutics, Inc. Biosynchronous transdermal drug delivery for longevity, anti-aging, fatigue management, obesity, weight loss, weight management, delivery of nutraceuticals, and the treatment of hyperglycemia, alzheimer's disease, sleep disorders, parkinson's disease, aids, epilepsy, attention deficit disorder, nicotine addiction, cancer, headache and pain control, asthma, angina, hypertension, depression, cold, flu and the like
US20060122127A1 (en) 2004-11-17 2006-06-08 Cypress Bioscience, Inc. Methods for reducing the side effects associated with mirtzapine treatment
US8512751B2 (en) 2004-12-20 2013-08-20 Collegium Pharmaceutical, Inc. Pharmaceutical compositions for sleep disorders
US20080009538A1 (en) 2005-03-21 2008-01-10 Phil Skolnick Methods and compositions for the treatment of urinary incontinence
AU2006236602B2 (en) 2005-04-15 2011-10-13 The Board Of Trustees Of The University Of Illinois Pharmacological treatment for sleep apnea
US20070021927A1 (en) 2005-07-21 2007-01-25 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Selective resonance of chemical structures
FR2889811B1 (fr) 2005-08-19 2009-10-09 Sanofi Aventis Sa Association d'un agent hypnotique a duree d'action longue et d'un agent hypnotique a duree d'action courte, composition pharmaceutique la contenant et son application en therapeutique.
EP2578216A1 (en) 2006-11-22 2013-04-10 Seaside Therapeutics, Inc. Methods of treating fragile x syndrome
WO2008122019A1 (en) 2007-04-02 2008-10-09 Cypress Biosciences, Inc. Improving the tolerability of both mirtazapine and reboxetine by using them in combination
EP2142183A2 (en) 2007-04-09 2010-01-13 Sepracor Inc. Methods and compositions comprising desvenlafaxine or duloxetine for treating sleep-related breathing disorders
US8415390B2 (en) 2008-05-30 2013-04-09 Microdose Therapeutx, Inc. Methods and compositions for administration of oxybutynin
US9119777B2 (en) 2008-05-30 2015-09-01 Microdose Therapeutx, Inc. Methods and compositions for administration of oxybutynin
WO2009023820A1 (en) 2007-08-16 2009-02-19 Cypress Biosciences, Inc. Improving the tolerability of a serotonin antagonist and a nsri, a snri or a rima by using them in combination
KR20100103844A (ko) 2007-12-21 2010-09-28 유란드, 인코포레이티드 테마제팜의 경구 붕해 타블릿 조성물
US20100204058A1 (en) 2009-01-28 2010-08-12 Howard Yuan-Hao Chang Profiling for Determination of Response to Treatment for Inflammatory Disease
EP2552205A4 (en) 2010-04-01 2014-01-01 Theravida Inc PROCESS FOR INCREASING SLEEP QUALITY
US8753327B2 (en) 2011-01-28 2014-06-17 Pfantastic Medical Research Institute, Llc Methods for treating obstructive sleep apnea
JP2012176958A (ja) 2012-04-20 2012-09-13 Watson Pharmaceuticals Inc （ｒ）−オキシブチニンおよび（ｒ）−デスエチルオキシブチニンによる平滑筋機能亢進の処置
EP2964185B1 (en) 2013-03-05 2021-11-10 Requis Pharmaceuticals Inc. Preparations for the treatment of sleep-related respiratory disorders
AU2015335391B2 (en) 2014-10-24 2018-06-21 Launx Biomedical Co., Ltd. Uses of duloxetine HCL medicament in preparing pharmaceutical composition for treatment of cancer
WO2016176177A1 (en) 2015-04-27 2016-11-03 Arena Pharmaceuticals, Inc. 5-ht2c receptor agonists and compositions and methods of use
US10004749B2 (en) 2015-07-22 2018-06-26 John Hsu Composition comprising a therapeutic agent and a respiratory stimulant and methods for the use thereof
US20180235934A1 (en) 2015-08-18 2018-08-23 Massachusetts Institute Of Technology Noradrenergic drug treatment of obstructive sleep apnea
MX2019012729A (es) * 2017-04-28 2019-12-19 Brigham & Womens Hospital Inc Metodos y composiciones para el tratamiento de apnea del sue?o.
AR114350A1 (es) 2018-01-31 2020-08-26 Res Institute At Nationwide Children’S Hospital Terapia genética para la distrofia muscular de cinturas del tipo 2c
CN113692277A (zh) 2019-02-08 2021-11-23 布里格姆妇女医院 用于治疗睡眠呼吸暂停的方法和组合物

Also Published As

Publication number Publication date
WO2019152475A1 (en) 2019-08-08
US20220378724A1 (en) 2022-12-01
BR112020015316A2 (pt) 2020-12-08
JP2021516218A (ja) 2021-07-01
MA52861A (fr) 2021-05-05
EA202091597A1 (ru) 2020-10-22
US20210038541A1 (en) 2021-02-11
AU2019214891A1 (en) 2020-08-20
MX2020008086A (es) 2021-02-15
IL276247A (en) 2020-09-30
US20240156753A1 (en) 2024-05-16
CA3089712A1 (en) 2019-08-08
KR20200115598A (ko) 2020-10-07
JP2023181322A (ja) 2023-12-21
CN111670050A (zh) 2020-09-15
EP3746126A1 (en) 2020-12-09
JP7422666B2 (ja) 2024-01-26
US11911351B2 (en) 2024-02-27

Similar Documents

Publication Publication Date Title
ZA201907158B (en) Methods and compositions for treating sleep apnea
IL276247A (en) Methods and materials for the treatment of sleep apnea
IL282600A (en) Composition and method for health care
IL271503A (en) Preparations and treatments for sleep disorders
EP3092033A4 (en) Method and apparatus for treating sleep apnea
PL3253443T3 (pl) Urządzenie do leczenia chrapania i bezdechu sennego
IL285197A (en) Methods and preparations for the treatment of sleep apnea
IL275626A (en) Preparations and methods for surface treatment
EP3866736A4 (en) METHODS AND DEVICES FOR THE TREATMENT OF SLEEP APNEA
HK1251168A1 (zh) 用於治療和/或預防腫瘤的沙粒病毒和產生具有(改善的)腫瘤消退特性的沙粒病毒的方法
IL280413A (en) Bismuth-thiol preparations and wound treatment methods
SG11202012055PA (en) Methods and compositions for preventing or treating calciphylaxis
IL269743A (en) Methods and preparations for the treatment of disease related to the retina with CCR-3 inhibitor inventions
LT3691649T (lt) Žaizdų gydymo kompozicijos ir būdai
SG11202102442WA (en) Methods and compositions for preventing and treating atherosclerosis and related diseases
IL260929B (en) Dental appliance system and method of forming thereof for treating sleep apnea
IL280348A (en) Surface treatment compositions and methods
ZA202002526B (en) New alcoxyamino derivatives for treating pain and pain related conditions
PT3810128T (pt) Composições para tratar e/ou prevenir doenças de agregação de proteinas
EP3720351A4 (en) METHODS AND SYSTEMS FOR THE TREATMENT OF SLEEP APNEA
IL307186A (en) Methods and preparations for treating sleep apnea
EP3746068A4 (en) COMPOSITIONS AND METHODS OF TREATMENT OF OBSTRUCTIVE SLEEP APNEA
IL235257A (en) Snoring and sleep apnea system
GB201913589D0 (en) Systems and methods for reducing snoring and/or sleep apnea
EP3624808A4 (en) PROCEDURES AND COMPOSITIONS FOR IMPROVED SLEEP